Interferon alfa-2a

Generic Name: Interferon alfa-2a

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 76543-88-9

Unique Ingredient Identifier: 47RRR83SK7

Background: Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Bioscie...

Indication: For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.

Associated Conditions: Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Chronic Myelogenous Leukemia (CML), Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Thrombocytosis

Associated Therapies: -

Clinical Trials

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Not Applicable

Recruiting

Conditions: Hepatitis B

Interventions: Drug: Nucleotide Analog
Drug: Interferon Alfa-2A

First Posted Date: 2018-12-11

Last Posted Date: 2023-05-08

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 400

Registration Number: NCT03771677

Locations: 🇨🇳
Chan Xie, Guangzhou, Guangdong, China

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Phase 3

Completed

Conditions: Behçet Disease
Uveitis

Interventions: Drug: Cyclosporine Pill
Drug: Interferon Alfa-2A

First Posted Date: 2017-07-06

Last Posted Date: 2021-02-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 28

Registration Number: NCT03209219

Locations: 🇨🇳
Peking Union Medical College, Beijing, Beijing, China

Bevacizumab in Metastatic Renal Cancer

Completed

Conditions: Renal Cell Cancer

Interventions: Drug: Bevacizumab
Drug: Interferon alpha-2a

First Posted Date: 2015-12-10

Last Posted Date: 2016-08-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 365

Registration Number: NCT02627144

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: TG-2349
Drug: Ribavirin
Drug: Interferon Alfa-2a

First Posted Date: 2015-01-19

Last Posted Date: 2023-07-14

Lead Sponsor: TaiGen Biotechnology Co., Ltd.

Target Recruit Count: 25

Registration Number: NCT02340962

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines

Phase 2

Terminated

Conditions: Cancer

Interventions: Drug: Interferon Alfa-2a

First Posted Date: 2014-06-10

Last Posted Date: 2014-07-25

Lead Sponsor: Duke University

Target Recruit Count: 11

Registration Number: NCT02159482

A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Phase 2

Completed

Conditions: Renal Cell Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: interferon alfa-2a

First Posted Date: 2008-11-24

Last Posted Date: 2015-05-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 146

Registration Number: NCT00796757

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Phase 2

Completed

Conditions: Nephroid Carcinoma
Adenocarcinoma
Renal Cell
Hypernephroid
Carcinoma

Interventions: Drug: interferon alfa-2a
Drug: RAD001(everolimus)
Drug: bevacizumab

First Posted Date: 2008-07-21

Last Posted Date: 2017-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 365

Registration Number: NCT00719264

Locations: 🇺🇸
City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(3), Duarte, California, United States
🇺🇸
USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States
🇺🇸
University of California at Los Angeles Dept. of Hem/Oncology, Los Angeles, California, United States

and more 7 locations

Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Drug: Temsirolimus
Drug: Bevacizumab
Drug: Interferon alpha-2a

First Posted Date: 2008-02-20

Last Posted Date: 2013-02-15

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 160

Registration Number: NCT00619268

Locations: 🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇫🇷
Centre Hospitalier Universitaire de Bordeaux - Hôpital St André, Bordeaux, France
🇫🇷
Centre Hospitalier Universiariare Lyon, Hôpital Lyon Sud, Lyon, France

and more 26 locations

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Phase 2

Completed

Conditions: Renal Cell Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: Interferon alfa-2a
Drug: Vinblastine

First Posted Date: 2007-08-24

Last Posted Date: 2014-10-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 25

Registration Number: NCT00520403

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Interferon Alfa-2a
Drug: Interleukin-2

First Posted Date: 2007-07-17

Last Posted Date: 2013-07-10

Lead Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Target Recruit Count: 310

Registration Number: NCT00502034

Locations: 🇮🇹
Pavia University Hospital, Pavia, Italy
🇮🇹
Ospedale "Guglielmo da Saliceto", Piacenza, Italy
🇮🇹
Modena University Hospital, Modena, Italy

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy